Targeting the p53-MDM2 interaction to treat cancer

British Journal of Cancer

Volumn 91, Issue 8, 2004, Pages 1415-1419

  Klein, C ^a   Vassilev, L T ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

MDM2; p53; Protein protein interaction; Small molecule

Indexed keywords

CHALCONE; CHLOROFUSIN; IMIDAZOLINE DERIVATIVE; NONAPEPTIDE; NUTLIN; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SHORT SURVEY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 7944239221     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602164     Document Type: Short Survey

References (52)

1. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3: 301-317
2. Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D (1997) Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 14: 1859-1868
3. Blommers MJJ, Fendrich G, Garcia-Echeverria C, Chene P (1997) On the interaction between p53 and MDM2: Transfer NOE study of a p53-derived peptide ligated to MDM2. J Am Chem Soc 119: 3425-3426
4. Bottger A, Bottger V, Garcia-Echeverria C, Chene P, Hochkeppel HK, Sampson W, Ang K, Howard SF, Picksley SM, Lane DP (1997a) Molecular characterization of the hdm2-p53 interaction. J Mol Biol 269: 744-756
5. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP (1997b) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 7: 860-869
6. Bottger V, Bottger A, Howard SF, Picksley SM, Chene P, Garcia-Echeverria C, Hochkeppel HK, Lane DP (1996) Identification of novel mdm2 binding peptides by phage display. Oncogene 13: 2141-2147
7. Chen J, Marechal V, Levine AJ (1993) Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13: 4107-4114
8. Chen L, Lu W, Agrawal S, Zhou W, Zhang R, Chen J (1999) Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med 5: 21-34
9. Chene P, Fuchs J, Bohn J, Garcia-Echeverria C, Furet P, Fabbro D (2000) A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J Mol Biol 299: 245-253
10. Chene P, Fuchs J, Carena I, Furet P, Garcia-Echeverria C (2002) Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett 529: 293-297
11. Dawson R, Muller L, Dehner A, Klein C, Kessler H, Buchner J (2003) The N-terminal domain of p53 is natively unfolded. J Mol Biol 332: 1131-1141
12. de Rozieres S, Maya R, Oren M, Lozano G (2000) The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19: 1691-1697
13. di Domenico R, Hansen S, Kaluza B, Mento E, Schumacher R (1999) Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity. In: EP99105721, Hoffmann F (ed) Switzerland: LA Roche AG
14. Duncan SJ, Cooper MA, Williams DH (2003) Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chem Commun (Camb) 7: 316-317
15. Duncan SJ, Gruschow S, Williams DH, McNicholas C, Purewal R, Hajek M, Gerlitz M, Martin S, Wrigley SK, Moore M (2001) Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J Am Chem Soc 123: 554-560
16. Fasan R, Dias RLA, Moehle K, Zerbe O, Vrijbloed JW, Obrecht D, Robinson JA (2004) Using a beta-Hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew Chem Int Edit 43: 2109-2112
17. Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96-107
18. Galatin PS, Abraham DJ (2001) QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction. Proteins 45: 169-175
19. Garcia-Echeverria C, Chene P, Blommers MJ, Furet P (2000) Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J Med Chem 43: 3205-3208
20. Garcia-Echeverria C, Furet P, Chene P (2001) Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction. Bioorg Med Chem Lett 11: 2161-2164
21. Geiger T, Husken D, Weiler J, Natt F, Woods-Cook KA, Hall J, Fabbro D (2000) Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides. Anticancer Drug Des 15: 423-430
22. Hainaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137
23. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208
24. Juven-Gershon T, Oren M (1999) Mdm2: the ups and downs. Mol Med 5: 71-83
25. Kumar SK, Hager E, Pettit C, Gurulingappa H, Davidson NE, Khan SR (2003) Design, synthesis, and evaluation of novel boronic - chalcone derivatives as antitumor agents. J Med Chem 46: 2813-2815
26. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953
27. Lai Z, Yang T, Kim YB, Sielecki TM, Diamond MA, Strack P, Rolfe M, Caligiuri M, Benfield PA, Auger KR, Copeland RA (2002) Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 99: 14734-14739
28. Lee H, Mok KH, Muhandiram R, Park KH, Suk JE, Kim DH, Chang J, Sung YC, Choi KY, Han KH (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J Biol Chem 275: 29426-29432
29. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
30. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME (2003) Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462-472
31. Momand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459
32. Momand J, Wu HH, Dasgupta G (2000) MDM2 - master regulator of the p53 tumor suppressor protein. Gene 242: 15-29
33. Monies de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206
34. O'Leary KA, Mendrysa SM, Vaccaro A, Perry ME (2004) Mdm2 regulates p53 independently of p19(ARF) in homeostatic tissues. Mol Cell Biol 24: 186-191
35. Picksley SM, Vojtesek B, Sparks A, Lane DP (1994) Immunochemical analysis of the interaction of p53 with MDM2: fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9: 2523-2529
36. Schon O, Friedler A, Freund S, Fersht AR (2004) Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J Mol Biol 336: 197-202
37. Shimizu H, Burch L, Smith A, Dornan D, Wallace M, Ball KL, Hupp TR (2002) The conformationally-flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2-binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 277: 28446-28458
38. Smart P, Lane EB, Lane DP, Midgley C, Vojtesek B, Lain S (1999) Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18: 7378-7386
39. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Muhlhahn P, Schumacher R, Hesse F, Kaluza B, Voelter W, Engh RA, Holak TA (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40: 336-344
40. Stommel JM, Wahl GM (2004) Accelerated MDM2 auto-degradation induced by DMA-damage kinases is required for p53 activation. Embo J 23: 1547-1556
41. Toogood PL (2002) Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem 45: 1543-1558
42. Uesugi M, Verdine GL (1999) The alpha-helical FXXPhiPhi motif in p53: TAP interaction and discrimination by MDM2. Proc Natl Acad Sci USA 96: 14801-14806
43. Vassilev LT (2004) Small-molecule inhibitors of p53-MDM2 binding: Research tools and potential cancer theraputics. Cell Cycle 3: 419-421
44. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848
45. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
46. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604
47. Wang H, Nan L, Yu D, Agrawal S, Zhang R (2001) Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 7: 3613-3624
48. Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S, Zhang R (1999) MDM2 oncogene as a target for cancer therapy: an antisense approach. Int J Oncol 15: 653-660
49. Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J, Debussche L, Wasylyk B (1999) p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18: 1921-1934
50. Zhang Z, Li M, Wang H, Agrawal S, Zhang R (2003) Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 100: 11636-11641
51. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R (2004) MDM2 is a negative regulator of p21WAF1/CIP1, Independent of p53. J Biol Chem 279: 16000-16006
52. Zhao J, Wang M, Chen J, Luo A, Wang X, Wu M, Yin D, Liu Z (2002) The initial evaluation of non-peptidic small-moleculre HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett 183: 69-77